284 related articles for article (PubMed ID: 23347343)
1. Optimizing patient derived mesenchymal stem cells as virus carriers for a phase I clinical trial in ovarian cancer.
Mader EK; Butler G; Dowdy SC; Mariani A; Knutson KL; Federspiel MJ; Russell SJ; Galanis E; Dietz AB; Peng KW
J Transl Med; 2013 Jan; 11():20. PubMed ID: 23347343
[TBL] [Abstract][Full Text] [Related]
2. Mesenchymal stem cell carriers protect oncolytic measles viruses from antibody neutralization in an orthotopic ovarian cancer therapy model.
Mader EK; Maeyama Y; Lin Y; Butler GW; Russell HM; Galanis E; Russell SJ; Dietz AB; Peng KW
Clin Cancer Res; 2009 Dec; 15(23):7246-55. PubMed ID: 19934299
[TBL] [Abstract][Full Text] [Related]
3. Dual therapy of ovarian cancer using measles viruses expressing carcinoembryonic antigen and sodium iodide symporter.
Hasegawa K; Pham L; O'Connor MK; Federspiel MJ; Russell SJ; Peng KW
Clin Cancer Res; 2006 Mar; 12(6):1868-75. PubMed ID: 16551872
[TBL] [Abstract][Full Text] [Related]
4. Systemically delivered measles virus-infected mesenchymal stem cells can evade host immunity to inhibit liver cancer growth.
Ong HT; Federspiel MJ; Guo CM; Ooi LL; Russell SJ; Peng KW; Hui KM
J Hepatol; 2013 Nov; 59(5):999-1006. PubMed ID: 23867315
[TBL] [Abstract][Full Text] [Related]
5. Infected cell carriers: a new strategy for systemic delivery of oncolytic measles viruses in cancer virotherapy.
Iankov ID; Blechacz B; Liu C; Schmeckpeper JD; Tarara JE; Federspiel MJ; Caplice N; Russell SJ
Mol Ther; 2007 Jan; 15(1):114-22. PubMed ID: 17164782
[TBL] [Abstract][Full Text] [Related]
6. Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer.
Galanis E; Hartmann LC; Cliby WA; Long HJ; Peethambaram PP; Barrette BA; Kaur JS; Haluska PJ; Aderca I; Zollman PJ; Sloan JA; Keeney G; Atherton PJ; Podratz KC; Dowdy SC; Stanhope CR; Wilson TO; Federspiel MJ; Peng KW; Russell SJ
Cancer Res; 2010 Feb; 70(3):875-82. PubMed ID: 20103634
[TBL] [Abstract][Full Text] [Related]
7. Oncolytic measles virus expressing the sodium iodide symporter to treat drug-resistant ovarian cancer.
Galanis E; Atherton PJ; Maurer MJ; Knutson KL; Dowdy SC; Cliby WA; Haluska P; Long HJ; Oberg A; Aderca I; Block MS; Bakkum-Gamez J; Federspiel MJ; Russell SJ; Kalli KR; Keeney G; Peng KW; Hartmann LC
Cancer Res; 2015 Jan; 75(1):22-30. PubMed ID: 25398436
[TBL] [Abstract][Full Text] [Related]
8. Oncolytic measles viruses encoding interferon beta and the thyroidal sodium iodide symporter gene for mesothelioma virotherapy.
Li H; Peng KW; Dingli D; Kratzke RA; Russell SJ
Cancer Gene Ther; 2010 Aug; 17(8):550-8. PubMed ID: 20379224
[TBL] [Abstract][Full Text] [Related]
9. Feasibility of Bone Marrow Mesenchymal Stem Cell-Mediated Synthetic Radiosensitive Promoter-Combined Sodium Iodide Symporter for Radiogenetic Ovarian Cancer Therapy.
Shi S; Li F; Wu L; Zhang L; Liu L
Hum Gene Ther; 2021 Aug; 32(15-16):828-838. PubMed ID: 33339472
[TBL] [Abstract][Full Text] [Related]
10. Intraperitoneal therapy of ovarian cancer using an engineered measles virus.
Peng KW; TenEyck CJ; Galanis E; Kalli KR; Hartmann LC; Russell SJ
Cancer Res; 2002 Aug; 62(16):4656-62. PubMed ID: 12183422
[TBL] [Abstract][Full Text] [Related]
11. MeV-Stealth: A CD46-specific oncolytic measles virus resistant to neutralization by measles-immune human serum.
Muñoz-Alía MÁ; Nace RA; Tischer A; Zhang L; Bah ES; Auton M; Russell SJ
PLoS Pathog; 2021 Feb; 17(2):e1009283. PubMed ID: 33534834
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of oncolytic measles virotherapy: eventual equilibrium between virus and tumor in an ovarian cancer xenograft model.
Peng KW; Hadac EM; Anderson BD; Myers R; Harvey M; Greiner SM; Soeffker D; Federspiel MJ; Russell SJ
Cancer Gene Ther; 2006 Aug; 13(8):732-8. PubMed ID: 16543921
[TBL] [Abstract][Full Text] [Related]
13. Polyinosinic acid decreases sequestration and improves systemic therapy of measles virus.
Liu YP; Tong C; Dispenzieri A; Federspiel MJ; Russell SJ; Peng KW
Cancer Gene Ther; 2012 Mar; 19(3):202-11. PubMed ID: 22116376
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of T cells as carriers for systemic measles virotherapy in the presence of antiviral antibodies.
Ong HT; Hasegawa K; Dietz AB; Russell SJ; Peng KW
Gene Ther; 2007 Feb; 14(4):324-33. PubMed ID: 17051248
[TBL] [Abstract][Full Text] [Related]
15. Preclinical efficacy of the oncolytic measles virus expressing the sodium iodide symporter in iodine non-avid anaplastic thyroid cancer: a novel therapeutic agent allowing noninvasive imaging and radioiodine therapy.
Reddi HV; Madde P; McDonough SJ; Trujillo MA; Morris JC; Myers RM; Peng KW; Russell SJ; McIver B; Eberhardt NL
Cancer Gene Ther; 2012 Sep; 19(9):659-65. PubMed ID: 22790962
[TBL] [Abstract][Full Text] [Related]
16. Human mesenchymal stromal cells deliver systemic oncolytic measles virus to treat acute lymphoblastic leukemia in the presence of humoral immunity.
Castleton A; Dey A; Beaton B; Patel B; Aucher A; Davis DM; Fielding AK
Blood; 2014 Feb; 123(9):1327-35. PubMed ID: 24345754
[TBL] [Abstract][Full Text] [Related]
17. Systemic therapy of disseminated myeloma in passively immunized mice using measles virus-infected cell carriers.
Liu C; Russell SJ; Peng KW
Mol Ther; 2010 Jun; 18(6):1155-64. PubMed ID: 20234340
[TBL] [Abstract][Full Text] [Related]
18. Tumor-associated macrophages infiltrate plasmacytomas and can serve as cell carriers for oncolytic measles virotherapy of disseminated myeloma.
Peng KW; Dogan A; Vrana J; Liu C; Ong HT; Kumar S; Dispenzieri A; Dietz AB; Russell SJ
Am J Hematol; 2009 Jul; 84(7):401-7. PubMed ID: 19507209
[TBL] [Abstract][Full Text] [Related]
19. Mesenchymal Stem Cell-Mediated Delivery of an Oncolytic Adenovirus Enhances Antitumor Efficacy in Hepatocellular Carcinoma.
Yoon AR; Hong J; Li Y; Shin HC; Lee H; Kim HS; Yun CO
Cancer Res; 2019 Sep; 79(17):4503-4514. PubMed ID: 31289131
[TBL] [Abstract][Full Text] [Related]
20. Human umbilical blood mononuclear cell-derived mesenchymal stem cells serve as interleukin-21 gene delivery vehicles for epithelial ovarian cancer therapy in nude mice.
Hu W; Wang J; He X; Zhang H; Yu F; Jiang L; Chen D; Chen J; Dou J
Biotechnol Appl Biochem; 2011; 58(6):397-404. PubMed ID: 22172102
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]